{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T16:22:56Z","timestamp":1775751776058,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Combined treatment with dabrafenib, a B-RAF inhibitor, and trametinib, a mitogen-activated protein kinase inhibitor, is an effective option for patients with metastatic melanoma. A few cases of acute kidney injury associated with tubulointerstitial nephritis and 1 case of nephrotic syndrome have been reported in patients on this drug combination; however, progressive renal injury has not been reported. In this case study, we report a patient with metastatic melanoma who developed glomerular capillary endothelial toxicity and progressive glomerular sclerosis during combination therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concern:<\/jats:title>\n            <jats:p>Our patient was an 80-year-old woman with a history of type 2 diabetes and chronic kidney disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis and intervention:<\/jats:title>\n            <jats:p>She was diagnosed with metastatic melanoma and commenced combination therapy with dabrafenib and trametinib.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Her renal function progressively deteriorated; by month 20 after treatment commencement, her serum creatinine level had increased from 1.59 to 3.74\u200amg\/dL. The first kidney biopsy revealed marked glomerular and endothelial cell damage. Her medication was stopped, but no improvement was evident. At 5\u200amonths after the first biopsy, her serum creatinine level had increased to 5.46\u200amg\/dL; a second kidney biopsy revealed focal segmental glomerular sclerosis and marked tubulointerstitial fibrosis. She was started on hemodialysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>We describe a patient with a metastatic melanoma who developed progressive kidney failure during treatment with dabrafenib and trametinib. The most prominent microscopy findings were glomerular endothelial damage in the initial kidney biopsy and accelerated glomerular sclerosis and tubulointerstitial fibrosis in the follow-up biopsy. We hypothesize that a decreased renal reserve and impairment of kidney repair capacity caused by inhibition of B-RAF, a downstream mediator of vascular endothelial growth factor, may explain the progressive kidney injury.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028485","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T13:20:59Z","timestamp":1641561659000},"page":"e28485","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Dabrafenib- and trametinib-associated glomerular toxicity"],"prefix":"10.1097","volume":"101","author":[{"given":"Eunmi","family":"Jo","sequence":"first","affiliation":[{"name":"Department of Nephrology, Pusan National University School of Medicine, Busan, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6257-8551","authenticated-orcid":false,"given":"Harin","family":"Rhee","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Pusan National University School of Medicine, Busan, Republic of Korea"},{"name":"Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"07","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"175346661876761","DOI":"10.1177\/1753466618767611","article-title":"Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience","volume":"12","author":"Khunger","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"R4-20250504","article-title":"Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib","author":"Seethapathy","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2016.12.013","article-title":"BRAF signaling pathway inhibition, podocyte injury, and nephrotic syndrome","volume":"70","author":"Perico","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000025904","article-title":"Role of glomerular endothelial damage in progressive renal disease","volume":"22","author":"Yamanaka","year":"1999","journal-title":"Kidney Blood Press Res"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"659013","DOI":"10.3389\/fmed.2021.659013","article-title":"Glomerular endothelial cell crosstalk with podocytes in diabetic kidney disease","volume":"8","author":"Mahtal","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"(Suppl 4)","key":"R8-20250504","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nep.13451","article-title":"Glomerular mesangial cell and podocyte injuries in diabetic nephropathy","volume":"23","author":"Tung","year":"2018","journal-title":"Nephrology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/CMR.0000000000000186","article-title":"Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib","volume":"25","author":"Jansen","year":"2015","journal-title":"Melanoma Res"},{"key":"R10-20250504","article-title":"Acute granulomatous interstitial nephritis in a patient with metastatic melanoma on targeted therapy with dabrafenib and trametinib \u2013 a case report","author":"Krelle","year":"2021","journal-title":"Cancer Rep"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13256-021-02766-w","article-title":"Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report","volume":"15","author":"Kyriazis","year":"2021","journal-title":"J Med Case Rep"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/CMR.0000000000000646","article-title":"Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF\/MEK inhibitors","volume":"30","author":"Thummalapalli","year":"2020","journal-title":"Melanoma Res"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","article-title":"Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib","volume":"1","author":"Jhaveri","year":"2015","journal-title":"JAMA Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00280-016-3086-7","article-title":"New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma","volume":"78","author":"Teuma","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14740338.2016.1164139","article-title":"BRAF inhibitors \u2013 do we need to worry about kidney injury?","volume":"15","author":"Wanchoo","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e7196","DOI":"10.1097\/MD.0000000000007196","article-title":"Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: a case report","volume":"96","author":"Maanaoui","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/bjd.12555","article-title":"Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas","volume":"169","author":"Regnier-Rosencher","year":"2013","journal-title":"Br J Dermatol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2215\/CJN.06100616","article-title":"Renal toxicities of novel agents used for treatment of multiple myeloma","volume":"12","author":"Wanchoo","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/diagnostics11040640","article-title":"Nephrotoxicity of anti-angiogenic therapies","volume":"11","author":"Van Wynsberghe","year":"2021","journal-title":"Diagnostics"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1111\/j.1523-1755.2004.00621.x","article-title":"The role of vascular endothelial growth factor (VEGF) in renal pathophysiology","volume":"65","author":"Schrijvers","year":"2004","journal-title":"Kidney Int"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.3390\/ijms20174246","article-title":"Preeclampsia: maternal systemic vascular disorder caused by generalized endothelial dysfunction due to placental antiangiogenic factors","volume":"20","author":"Tomimatsu","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2215\/CJN.12081115","article-title":"Preeclampsia: updates in pathogenesis, definitions, and guidelines","volume":"11","author":"Phipps","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cell.2012.08.037","article-title":"Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function","volume":"151","author":"Jin","year":"2012","journal-title":"Cell"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev-physiol-021115-105412","article-title":"Vascular growth factors and glomerular disease","volume":"78","author":"Bartlett","year":"2016","journal-title":"Annu Rev Physiol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.3390\/ijms21155294","article-title":"VEGF-A in cardiomyocytes and heart diseases","volume":"21","author":"Braile","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"e0234492","DOI":"10.1371\/journal.pone.0234492","article-title":"The soluble VEGF receptor sFlt-1 contributes to endothelial dysfunction in IgA nephropathy","volume":"15","author":"Zhai","year":"2020","journal-title":"PLoS One"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"e75759","DOI":"10.1371\/journal.pone.0075759","article-title":"An Increase in vascular endothelial growth factor (VEGF) and VEGF soluble receptor-1 (sFlt-1) are associated with early recurrent spontaneous abortion","volume":"8","author":"Pang","year":"2013","journal-title":"PLoS One"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ckj\/sfv149","article-title":"Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network","volume":"9","author":"Wanchoo","year":"2016","journal-title":"Clin Kidney J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:11:36Z","timestamp":1746331896000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028485"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028485","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"2021-11-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}